İsrail - İbranice - Ministry of Health

lapidot medical import and marketing ltd - deferiprone - טבליות מצופות פילם - deferiprone 500 mg - deferiprone - deferiprone - for the treatment of iron overload in patients over 6 years old with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

İsrail - İbranice - Ministry of Health

lapidot medical import and marketing ltd - deferiprone - תמיסה (פומי) - deferiprone 100 mg / 1 ml - deferiprone - deferiprone - for the treatment of iron overload in patients over 6 years old with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

İsrail - İbranice - Ministry of Health

lapidot medical import and marketing ltd - deferiprone - טבליות מצופות פילם - deferiprone 1000 mg - deferiprone

İsrail - İbranice - Ministry of Health

taro pharmaceutical industries ltd - deferiprone - טבליה - deferiprone 500 mg - deferiprone

İsrail - İbranice - Ministry of Health

taro pharmaceutical industries ltd - deferiprone - טבליות מצופות פילם - deferiprone 1000 mg - deferiprone

İsrail - İbranice - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

İsrail - İbranice - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

İsrail - İbranice - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

İsrail - İbranice - Ministry of Health

remedix care ltd - glycine; l- alanine; l- aspartic acid; l- cysteine; l- glutamic acid; l- isoleucine; l- leucine; l- lysine; l- methionine; l- ornithine hydrochloride; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; taurine - תמיסה לאינפוזיה - l- valine 0.76 g / 100 ml; l- tyrosine 0.045 g / 100 ml; l- tryptophan 0.2 g / 100 ml; l- threonine 0.37 g / 100 ml; taurine 0.06 g / 100 ml; l- serine 0.4 g / 100 ml; l- proline 0.3 g / 100 ml; l- phenylalanine 0.42 g / 100 ml; l- ornithine hydrochloride 0.318 g / 100 ml; l- methionine 0.24 g / 100 ml; l- lysine 1.1 g / 100 ml; l- leucine 1.0 g / 100 ml; l- isoleucine 0.67 g / 100 ml; l-histidine 0.38 g / 100 ml; glycine 0.4 g / 100 ml; l- glutamic acid 1.0 g / 100 ml; l- cysteine 0.189 g / 100 ml; l- aspartic acid 0.6 g / 100 ml; l-arginine 0.84 g / 100 ml; l- alanine 0.8 g / 100 ml - lysine - lysine - primene 10 % is indicated in 1) children and infants 2) neonates at term or premature of normal or low birth weight when oral or enteral nutrition is impossible insufficient or contraindicated.

İsrail - İbranice - Ministry of Health

cure medical & technical supply - aminoacetic acid; calcium chloride dihydrate; fish oil; glucose monohydrate; l- alanine; l- isoleucine; l- leucine; l- lysine acetate; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; magnesium sulfate heptahydrate; olive oil; potassium chloride; sodium acetate trihydrate; sodium glycerophosphate hydrate; soybean oil; taurine; triglycerides, medium-chain; zinc sulfate heptahydrate - תחליב לאינפוזיה - fish oil 30 g / 1000 ml; olive oil 50 g / 1000 ml; triglycerides, medium-chain 60 g / 1000 ml; soybean oil 60 g / 1000 ml; zinc sulfate heptahydrate 0.023 g / 1000 ml; sodium acetate trihydrate 5.62 g / 1000 ml; potassium chloride 4.48 g / 1000 ml; magnesium sulfate heptahydrate 2.47 g / 1000 ml; sodium glycerophosphate hydrate 4.18 g / 1000 ml; calcium chloride dihydrate 0.74 g / 1000 ml; l- valine 6.2 g / 1000 ml; l- tyrosine 0.40 g / 1000 ml; l- tryptophan 2.0 g / 1000 ml; l- threonine 4.4 g / 1000 ml; taurine 1.0 g / 1000 ml; l- serine 6.5 g / 1000 ml; l- proline 11.2 g / 1000 ml; l- phenylalanine 5.1 g / 1000 ml; l- methionine 4.3 g / 1000 ml; l- leucine 7.4 g / 1000 ml; l- isoleucine 5.0 g / 1000 ml; l-histidine 3.0 g / 1000 ml; l-arginine 12.0 g / 1000 ml; l- alanine 14.0 g / 1000 ml; glucose monohydrate 462 g / 1000 ml; l- lysine acetate 9.3 g / 1000 ml; aminoacetic acid 11.0 g / 1000 ml - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.